A trial shows soticlestat reduces convulsive seizures in young individuals with Dravet syndrome, indicating potential benefits.
Although statistical significance was narrowly missed, soticlestat showed a numerical benefit over placebo for convulsive seizure decrease. Clinically meaningful benefits across multiple secondary endpoints were observed. No new safety concerns emerged.
No takes yet. Share an insight, caveat, or question.
Sullivan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: